Forbes June 5, 2024
Dave Wessner

An FDA advisory committee recommended the development of a new Covid-19

vaccine at its meeting on Wednesday. According to the panel, vaccine manufacturers should design updated vaccines to target the JN.1 variant of SARS-CoV-2. Ideally, these updated vaccines will be available in the fall.

The Vaccines and Related Biological Products Advisory Committee of the FDA evaluated the effectiveness of the current vaccines and discussed the need for a new vaccine formulation. Representatives from Moderna, Pfizer-BioNtech, and Novavax presented data about the protection offered by current vaccines against emerging variants and the potential benefits of vaccines specifically targeting these new strains.

Following the presentations and a period of public comment, the panel voted unanimously to recommend that the 2024-2025 Covid-19 vaccine...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Related Articles:
STAT+: Trump’s FDA director pick has a history of criticizing the agency. Here are seven examples
Trump names nominees to lead CDC, FDA, and his pick for surgeon general
Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose
New FDA Panel Weighs In on Regulating Generative AI in Healthcare
Johns Hopkins surgeon Makary is Trump’s pick to lead FDA

Share This Article